LPL Financial LLC Boosts Position in Phibro Animal Health Corporation $PAHC

LPL Financial LLC grew its stake in Phibro Animal Health Corporation (NASDAQ:PAHC) by 46.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 128,335 shares of the company’s stock after buying an additional 40,889 shares during the quarter. LPL Financial LLC owned approximately 0.32% of Phibro Animal Health worth $2,741,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Sterling Capital Management LLC increased its position in Phibro Animal Health by 2.4% in the fourth quarter. Sterling Capital Management LLC now owns 18,762 shares of the company’s stock worth $394,000 after buying an additional 448 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Phibro Animal Health in the fourth quarter worth about $29,000. Price T Rowe Associates Inc. MD increased its position in Phibro Animal Health by 9.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,668 shares of the company’s stock worth $372,000 after buying an additional 1,565 shares in the last quarter. Lazard Asset Management LLC increased its position in Phibro Animal Health by 2,739.7% in the fourth quarter. Lazard Asset Management LLC now owns 1,647 shares of the company’s stock worth $34,000 after buying an additional 1,589 shares in the last quarter. Finally, Cetera Investment Advisers increased its position in Phibro Animal Health by 18.9% in the first quarter. Cetera Investment Advisers now owns 11,550 shares of the company’s stock worth $247,000 after buying an additional 1,840 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Wall Street Analysts Forecast Growth

PAHC has been the subject of several research analyst reports. BNP Paribas upgraded Phibro Animal Health to a “hold” rating in a research report on Monday, June 16th. Wall Street Zen upgraded Phibro Animal Health from a “hold” rating to a “buy” rating in a research report on Friday, May 9th. BNP Paribas Exane upgraded Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 target price for the company in a research report on Monday, June 16th. JPMorgan Chase & Co. upgraded Phibro Animal Health from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $25.00 to $35.00 in a research report on Monday, July 7th. Finally, Morgan Stanley set a $26.00 target price on Phibro Animal Health and gave the stock an “equal weight” rating in a research report on Wednesday, June 25th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $24.40.

Phibro Animal Health Stock Up 0.3%

Phibro Animal Health stock opened at $30.67 on Monday. The company has a debt-to-equity ratio of 2.67, a current ratio of 2.91 and a quick ratio of 1.23. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of 39.32, a PEG ratio of 0.51 and a beta of 0.80. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $31.80. The business has a fifty day moving average price of $27.57 and a 200-day moving average price of $23.80.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd will be paid a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Wednesday, September 3rd. Phibro Animal Health’s payout ratio is currently 61.54%.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.